Business Description
![Zealand Pharma A/S Zealand Pharma A/S logo](https://static.gurufocus.com/logos/0C0000394J.png?14)
Zealand Pharma A/S
ISIN : DK0060257814
Compare
Compare
Traded in other countries / regions
ZEAL.Denmark0NZU.UKZLDPF.USA22Z.Germany IPO Date
2010-12-22Description
Zealand Pharma A/S is a biotechnology company. It is focused on the discovery, design, and development of peptide-based medicines. The company's product pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The company has out-licensed a peptide program to Boehringer Ingelheim that has been moved ahead into early clinical development: a once-weekly novel dual-acting GLP-1/glucagon agonist for the treatment of obesity and/or Type 2 diabetes.
Financial Strength
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 5.16 | |||||
Equity-to-Asset | 0.79 | |||||
Debt-to-Equity | 0.14 | |||||
Debt-to-EBITDA | -0.54 | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | 52.2 | |||||
Beneish M-Score | -1.62 | |||||
WACC vs ROIC |
Growth Rank
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 6.6 | |||||
3-Year EBITDA Growth Rate | 10.7 | |||||
3-Year EPS without NRI Growth Rate | 16.8 | |||||
3-Year FCF Growth Rate | 24.7 | |||||
3-Year Book Growth Rate | -4 |
Momentum Rank
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 71.38 | |||||
9-Day RSI | 75.21 | |||||
14-Day RSI | 73.79 | |||||
6-1 Month Momentum % | 63.85 | |||||
12-1 Month Momentum % | 150 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 12.3 | |||||
Quick Ratio | 12.28 | |||||
Cash Ratio | 7.28 | |||||
Days Inventory | 131.55 | |||||
Days Sales Outstanding | 148.6 | |||||
Days Payable | 3357.04 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -13.6 | |||||
Shareholder Yield % | -3.98 |
Profitability Rank
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 93.1 | |||||
Operating Margin % | -190.95 | |||||
Net Margin % | -214.6 | |||||
FCF Margin % | -139.17 | |||||
ROE % | -42.71 | |||||
ROA % | -33.18 | |||||
ROIC % | -140.18 | |||||
ROC (Joel Greenblatt) % | -182.26 | |||||
ROCE % | -36.42 | |||||
Years of Profitability over Past 10-Year | 1 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 165.79 | |||||
PB Ratio | 20.83 | |||||
Price-to-Tangible-Book | 20.91 | |||||
EV-to-EBIT | -90.16 | |||||
EV-to-EBITDA | -90.99 | |||||
EV-to-Revenue | 190.06 | |||||
EV-to-FCF | -136.64 | |||||
Price-to-Net-Current-Asset-Value | 22.38 | |||||
Price-to-Net-Cash | 46.97 | |||||
Earnings Yield (Greenblatt) % | -1.11 | |||||
FCF Yield % | -0.71 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Zealand Pharma A/S Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | 46.166 | ||
EPS (TTM) (€) | -1.689 | ||
Beta | 0.81 | ||
Volatility % | 57.61 | ||
14-Day RSI | 73.79 | ||
14-Day ATR (€) | 5.211454 | ||
20-Day SMA (€) | 104.2 | ||
12-1 Month Momentum % | 150 | ||
52-Week Range (€) | 28.6 - 129.8 | ||
Shares Outstanding (Mil) | 70.65 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 5 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Zealand Pharma A/S Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Zealand Pharma A/S Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
Zealand Pharma A/S Frequently Asked Questions
What is Zealand Pharma A/S(FRA:22Z)'s stock price today?
The current price of FRA:22Z is €124.00. The 52 week high of FRA:22Z is €129.80 and 52 week low is €28.60.
When is next earnings date of Zealand Pharma A/S(FRA:22Z)?
The next earnings date of Zealand Pharma A/S(FRA:22Z) is 2024-08-15.
Does Zealand Pharma A/S(FRA:22Z) pay dividends? If so, how much?
Zealand Pharma A/S(FRA:22Z) does not pay dividend.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |